This case report describes two patients with chronic lymphocytic leukemia (CLL) who presented with concomitant nephrotic syndrome and significant proteinuria. The patients were treated with obinutuzumab and venetoclax. No comparator group was reported.
For Patient 1, the report notes complete clinical resolution of nephrotic syndrome and a marked reduction in proteinuria. For Patient 2, nephrotic syndrome resolved within a few weeks, with proteinuria completely resolving. This patient also achieved complete remission of CLL, as demonstrated by computed tomography and flow cytometry after treatment completion, and remained in sustained remission with proteinuria persistently below the nephrotic range at the last follow-up. Specific effect sizes, absolute numbers, and statistical measures were not reported for these outcomes.
Safety and tolerability data were not reported. Key limitations include the very small sample size of two cases, the observational case report design, and the absence of a comparator group. Funding and conflicts of interest were not reported.
This report documents an association between obinutuzumab/venetoclax treatment and resolution of nephrotic syndrome in two specific CLL patients. Due to the design and rarity of the condition, this evidence is of very low certainty and does not establish causality. It serves primarily to highlight awareness of this rare complication and a potential treatment association that requires validation in controlled studies.
A medical team described the experience of two patients who had both chronic lymphocytic leukemia (CLL), a type of blood cancer, and a related kidney problem called nephrotic syndrome. Nephrotic syndrome causes the kidneys to leak large amounts of protein into the urine, which can lead to swelling and other health issues. The doctors treated these patients with a combination of two targeted cancer drugs: obinutuzumab and venetoclax.
In both patients, the treatment was followed by a resolution of their nephrotic syndrome symptoms and a significant reduction in protein in their urine. For one patient, the improvement happened within weeks, and they remained in remission from both the kidney issue and their CLL at their last check-up. The report did not mention any specific side effects or safety problems from the treatment in these two individuals.
It is very important to understand that this is a case report involving only two people. There was no comparison group, and the condition itself is rare. This means we cannot say the treatment caused the improvement or that it would work for anyone else. The results are a promising observation that may guide future research, but they are not proof of effectiveness.
Readers should see this as an early, hopeful note from doctors about a potential treatment approach for a complex and rare complication of CLL. It highlights that kidney problems can occur with this cancer and may sometimes improve when the cancer is treated. Patients with similar conditions should discuss all treatment options with their own healthcare team, as this report does not establish a new standard of care.
What this means for you: A two-patient report suggests a possible link between CLL treatment and kidney improvement, but more research is needed.
View Original Abstract ↓
IntroductionNephrotic syndrome caused by membranoproliferative glomerulonephritis (MPGN) related to chronic lymphocytic leukemia (CLL) is a rare condition. Due to the rarity, no standard of care has been established yet. The combination of rituximab, chlorambucil and fludarabin was described as an effective therapeutic regimen. However, the efficacy of the novel therapeutic options in CLL-induced nephrotic syndrome are rarely reported so far.Materials and methodsWe report two cases of patients with CLL suffering from concomitant nephrotic syndrome with significant proteinuria. The patients have consented to the evaluation and publication of their data. The patients received their initial diagnosis at our clinic and were followed for approximately 3 years.ResultsThe first patient, a 44-year old female with B-CLL, Binet A, and a low risk CLL-IPI score. Initially lupus nephritis was suspected to be associated with MPGN. However, despite the immunosuppressive treatment with mycophenolate mofetil and prednisolone no disease control was achieved. Consequently, CLL-associated nephrotic syndrome was assumed, and treatment with obinutuzumab and venetoclax was initiated. Six weeks after therapy initiation, the patient showed complete clinical resolution of nephrotic syndrome, accompanied by a marked reduction in proteinuria. The second patient, a 73-year old man, diagnosed with B-CLL, Binet C, CLL-IPI score intermediate risk presenting with concomitant MPGN. Treatment with obinutuzumab and venetoclax was initiated. Clinically, the nephrotic syndrome resolved within a few weeks after the initiation of therapy. Final assessment after completion of treatment by computed tomography and flow cytometry demonstrated complete remission of CLL. In addition, proteinuria completely resolved. At the last follow-up, the patient remains in sustained remission, with proteinuria persistently below the nephrotic range.ConclusionIn this report, we present two cases of CLL-related nephrotic syndromes, successfully treated with obinutuzumab and venetoclax. Furthermore, we emphasize the importance of awareness of this rare complication in patients with CLL.
